Personalis provides advanced cancer genomic sequencing and analysis for precision oncology. Its platforms profile tumors and track molecular residual disease to support clinical decision-making and biopharma drug development. Customers include academic centers, clinical labs, and pharmaceutical companies running oncology trials and companion diagnostics programs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 20.6 | — | -15.8 | — |
| Q2 2025 | 17.2 | — | -20.1 | — |
| Q3 2025 | 14.5 | — | -21.6 | — |
| Q4 2025 | 17.3 | — | -23.8 | — |
| Q1 2026 | 15.5 | -24.9% | -30 | — |
| Q2 2026 | 22.4 | 30% | -31.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Progress Software Corporation (PRGS), FirstSun Capital Bancorp (FSUN), Neutron Holdings, Inc. (LIME), NextDecade Corporation (NEXT), TriCo Bancshares (TCBK), EverCommerce Inc. (EVCM)